The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Thackray Helen M. since 2016.
This trader's CIK number is 1589725.
At the time of last reporting, Thackray Helen M. was the Chief R&D Officer of Biocryst Pharmaceuticals Inc. (stock ticker symbol BCRX).
Also see all insider trading activities at Biocryst Pharmaceuticals Inc.
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2017 | GLYC | 0 | $0 | 8,000 | $111,440 | 0 | $0 |
| 2016 | GLYC | 0 | $0 | 28,000 | $197,973 | 0 | $0 |
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2024 | BCRX | 30,000 | $175,800 | 0 | $0 | 0 | $0 |
| 2023 | BCRX | 0 | $0 | 7,000 | $58,029 | 0 | $0 |
| 2022 | BCRX | 0 | $0 | 7,600 | $123,120 | 0 | $0 |
2. Biocryst Pharmaceuticals Inc (BCRX)
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2017-12-08 | GLYC | Sale | 2,000 | 15.01 | 30,020 |
| 2017-09-18 | GLYC | Sale | 2,000 | 13.00 | 26,000 |
| 2017-05-25 | GLYC | Sale | 2,000 | 15.57 | 31,140 |
| 2017-05-19 | GLYC | Sale | 2,000 | 12.14 | 24,280 |
| 2016-10-03 | GLYC | Sale | 4,000 | 7.00 | 28,020 |
| 2016-07-20 | GLYC | Sale | 2,000 | 8.00 | 16,000 |
| 2016-07-05 | GLYC | Sale | 10,136 | 7.01 | 71,053 |
| 2016-07-06 | GLYC | Sale | 6,796 | 6.68 | 45,397 |
| 2016-07-01 | GLYC | Sale | 5,068 | 7.40 | 37,503 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2024-05-14 | BCRX | Buy | 30,000 | 5.86 | 175,800 |
| 2023-04-03 | BCRX | Sale | 7,000 | 8.29 | 58,029 |
| 2022-04-01 | BCRX | Sale | 7,600 | 16.20 | 123,120 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Thackray Helen M. (Chief R&D Officer of Biocryst Pharmaceuticals Inc at the time of this reporting) see the Securities and Exchange Commission (SEC) website.